249 related articles for article (PubMed ID: 30570418)
1. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations.
Fernandez Romero GA; Beros J; Criner G
Expert Rev Respir Med; 2019 Feb; 13(2):125-132. PubMed ID: 30570418
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.
Mkorombindo T; Dransfield MT
Int J Chron Obstruct Pulmon Dis; 2019; 14():1779-1787. PubMed ID: 31496677
[TBL] [Abstract][Full Text] [Related]
4. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
5. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.
Pavord ID; Chapman KR; Bafadhel M; Sciurba FC; Bradford ES; Schweiker Harris S; Mayer B; Rubin DB; Yancey SW; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2021; 16():1755-1770. PubMed ID: 34163157
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-5 in COPD.
Narendra DK; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2019; 14():1045-1051. PubMed ID: 31190789
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab-based therapy in asthma: an update.
Walsh GM
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
[TBL] [Abstract][Full Text] [Related]
11. The safety of mepolizumab for the treatment of asthma.
Leung E; Al Efraij K; FitzGerald JM
Expert Opin Drug Saf; 2017 Mar; 16(3):397-404. PubMed ID: 28116937
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
13. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.
Condreay LD; Gao C; Bradford E; Yancey SW; Ghosh S
Respir Med; 2019 Aug; 155():26-28. PubMed ID: 31295674
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
16. T2 Biologics for Chronic Obstructive Pulmonary Disease.
Yousuf A; Ibrahim W; Greening NJ; Brightling CE
J Allergy Clin Immunol Pract; 2019; 7(5):1405-1416. PubMed ID: 31076058
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
18. Biologic Drugs: A New Target Therapy in COPD?
Yousuf A; Brightling CE
COPD; 2018 Apr; 15(2):99-107. PubMed ID: 29683730
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Respir Investig; 2021 Jul; 59(4):478-486. PubMed ID: 33849780
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
